Responsibilities and Compliance Requirements for Independent Directors of U.S. Public Companies

The responsibilities of independent directors of U.S. publicly listed companies go far beyond merely lending their names, attending a few board meetings, and signing a few documents. Truly effective independent directors must hold firm ground within the boardroom, speak with authority, and shoulder genuine accountability. In 2025, the U.S. Securities and Exchange Commission (SEC) issued successive updates to the supplementary provisions of the Corporate Governance Guidelines for Public Companies, placing special emphasis on independent directors’ substantive involvement in three critical areas the quality of ESG disclosures; the assessment of independence for compensation committees; and oversight of cybersecurity risks. These are not merely paper requirements-multiple enforcement cases have already demonstrated that, when companies face liability arising from financial fraud or data breaches, courts are increasingly examining whether independent directors fulfilled their duty of “reasonable diligence.” Examples include whether directors reviewed third-party audit working papers prior to financial statement approval, or whether they submitted written inquiries to management regarding data security agreements with key suppliers. The boundaries of responsibility are narrowing; formal compliance alone is no longer sufficient.

Over the past decade, many China-based U.S.-listed companies-or those pursuing initial public offerings (IPOs) in the United States-have habitually treated independent directors as mere “backdrops” selecting a few well-known academics or retired senior executives solely to satisfy exchange-mandated numerical thresholds. However, in 2025, Nasdaq revised Listing Rule 5605, explicitly requiring that the Nominating and Corporate Governance Committee consist entirely of independent directors-and at least one member must possess “financial literacy” (a standard extending beyond mere CPA certification to encompass practical experience, such as having led quarterly financial reporting reviews for publicly traded companies). This amendment has directly prompted several technology firms preparing for IPOs to initiate independent director searches six months earlier than planned-not relying on executive search firms’ bundled recommendations, but instead proactively engaging seasoned practitioners who have served for at least three full terms on audit committees of SP 500 companies.

Duties must be documented-“remembering having attended meetings” is insufficient.

Regulatory logic is becoming increasingly clear determinations of whether directors have fulfilled their obligations hinge not on title or prestige, but on observable behavioral patterns. The following five items have now emerged as high-frequency inspection points in examinations conducted by both the SEC and the Public Company Accounting Oversight Board (PCAOB)

1. Prior to each board meeting, did the director receive the complete set of management presentation materials-including memoranda on sensitive matters-and were challenges to key assumptions explicitly reflected in the official meeting minutes?

2. Did the director independently assess the selection process for the annual external auditor-including comparative analysis of changes in audit fees over the past three years against corresponding shifts in audit scope and workload?

3. Did the director convene a closed-door session specifically to discuss the CEO succession plan, produce a written evaluation summary, and formally submit it to the full board?

4. For major MA transactions, did the director commission an independent valuation opinion from a third-party advisor-rather than relying solely on the transaction advisory report provided by the investment bank?

5. Prior to quarterly earnings releases, did the director issue written inquiry letters to the CFO concerning matters such as changes in revenue recognition policies or abnormal aging patterns in large accounts receivable-and retain documented responses thereto?

Localization efforts must guard against “regulatory incompatibility.”

Many China-based companies appoint independent directors familiar with A-share regulatory norms but lacking intuitive grasp of U.S. disclosure timing expectations. For instance, the SEC mandates disclosure of a “Material Adverse Change” (MAC) within four business days-but some companies continue operating under domestic habits of “internal notification first, followed by unified messaging,” resulting in independent directors unknowingly approving delayed disclosures. In March 2025, a medical device company announced receipt of an FDA warning letter only on the sixth day after its issuance. Although the independent directors were not named as defendants, the law firm representing them was placed by the SEC on the “High-Risk Independent Director Advisor List”; going forward, that firm must submit additional documentation detailing its directors’ processes before accepting new engagements.

The above outlines the core responsibilities and operational imperatives currently borne by independent directors of U.S. publicly listed companies-offering practical insight and actionable guidance.